An Act to amend the Code of Virginia by adding in Title 59.1 a chapter numbered 22.25, consisting of a section numbered 59.1-284.46, relating to Pharmaceutical Substance Manufacturing Grant Fund.
Summary
HB1076 creates the Pharmaceutical Substance Manufacturing Grant Fund in the Virginia Code and authorizes the Commonwealth to provide performance-based grants to a single qualifying pharmaceutical substance manufacturer. The bill defines a qualified company as one that, on or after July 1, 2025 and before July 1, 2045, is expected to make at least a $4 billion capital investment and create and maintain at least 500 new full-time jobs in Albemarle County. The grants may total up to $191,255,000 over the life of the program, with annual payments capped at $34 million and generally spread over up to 20 fiscal years.
The bill sets detailed eligibility, reporting, and oversight requirements. A company must enter into a memorandum of understanding with the Commonwealth and the Virginia Economic Development Partnership Authority, then annually document its capital investment and job creation to receive each installment. The Secretary of Commerce and Trade must certify the amount due, and payments are subject to annual appropriation by the General Assembly. The fund is nonreverting, and any unused balances remain in the fund from year to year. The bill also allows the Commonwealth to inspect relevant records, while preserving confidentiality for properly identified proprietary documents.
Impact
This measure adds a new economic development grant program to Title 59.1 of the Code of Virginia and creates a special nonreverting state treasury fund to finance grants for pharmaceutical manufacturing investment. It affects state budgeting and appropriations by committing the Commonwealth to a potential long-term grant obligation, but only if the General Assembly appropriates money each year and the company meets performance benchmarks. The practical effect is to provide a large, targeted incentive package for a major pharmaceutical manufacturing project in Albemarle County, with oversight by the Secretary of Commerce and Trade, the Comptroller, and VEDP.
Sentiment
The bill appears to have been broadly supported and moved through the legislature with strong bipartisan or near-unanimous committee and floor votes. It passed subcommittee, Appropriations, Finance and Appropriations, and both chambers with little recorded opposition, suggesting general agreement on the economic development rationale. The vote history indicates the proposal was treated as a significant but acceptable state incentive package rather than a controversial policy change.
Contention
The main potential point of contention is the size and duration of the public commitment: up to $191.255 million over 20 years for a single company, with annual payments contingent on appropriations and performance. Critics could question whether the state should offer such a large subsidy, whether the job and investment thresholds are sufficiently protective of public funds, and whether the benefits will justify the cost. Supporters, by contrast, likely view the bill as a strategic tool to attract a major pharmaceutical manufacturing investment and associated high-wage employment to Virginia.